Recently we have seen a surge in Ebola-related stocks across the board, but Friday trading brings a mixed view for this group.

Allied Healthcare Products Inc. (NASDAQ: AHPI) in Friday trading was trading down about 12% to $2.54 from the previous close of $2.94. In recent days shares have hit as high as $3.70, riding the Ebola wave. This producer of respiratory therapy equipment is only dealing will a small setback Friday, compared to the gains that it has made in the past week. The consensus analyst price target is $4.51 and the stock has a 52-week trading range of $1.60 to $3.90.

Chimerix Inc. (NASDAQ: CMRX) was trading at $34.96, down over 1% from its previous close of $35.40. The stock was initially positive Friday morning but then moved into the red on the day. This is a small step backward for this biopharmaceutical company, as it had posted significant gains for Wednesday and Thursday. The company’s stock has a consensus analyst price target of $37.14 and a 52-week trading range of $12.96 to $37.00.

ALSO READ: Top Biotech Stocks That Could Explode Higher After Huge Sell-Off

iBio Inc. (NYSEMKT: IBIO) has traded up about 21% at $2.29 from its previous close of $1.89. The stock has risen over the past couple of days due to news that it would partner with Calibur Pharmaceuticals to help produce an Ebola treatment, the main point being that it is part of a larger government effort. The stock has a consensus analyst price target of $3.00 and a 52-week trading range of $0.24 to $2.73.

Lakeland Industries Inc. (NASDAQ: LAKE), having seen some of the biggest gains out of the group, was down on Friday over 12% to $18.10 from the previous close of $20.69. The stock has gained roughly 317% to $29.00, its highest close in October, from $6.95 at the beginning of Lakeland’s rally early this month. The consensus analyst price target is $7.35 and the 52-week trading range is $4.75 to $29.55.

Sarepta Therapeutics Inc. (NASDAQ: SRPT) has seen a steady increase in its shares over the past week to its close Thursday at $22.30. Friday shares were up almost 6% to $23.60. This medical research and drug development company is just returning to its relative high levels from September. Shares have a consensus analyst price target of $37.94 and a 52-week trading range of $12.12 to $46.27.

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) has been trading down about 3% to $22.10 from its previous closing price of $22.81. This experimental Ebola treatment company has been on the decline this week, despite other Ebola-related companies gaining on the market’s fears. Tekmira has fallen about 24% over the past two weeks to close Thursday at $22.81 from its relative high of $29.93. The stock has a consensus analyst price target of $28.88 and a 52-week trading range of $7.17 to $31.48.

ALSO READ: J.P. Morgan Sees Big Buying Opportunity in Battered Solar Stocks

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.